Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.88 |
| ▸ | LMNA | P02545 | 8/20 | 0.88 |
| ▸ | NPC1 | O15118 | 6/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.88 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.88 |
| ▸ | RELA | Q04206 | 1/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178968 | 0.94 | RAB9A (1.00) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL15190160 | 0.84 | RAB9A (0.64) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1177933 | 0.84 | LMNA (0.88) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1178783 | 0.82 | RAB9A (0.68) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1177874 | 0.82 | RAB9A (0.64) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1178279 | 0.82 | RAB9A (0.64) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1178780 | 0.81 | RAB9A (0.63) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1178425 | 0.81 | RAB9A (0.63) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL1179184 | 0.81 | LMNA (0.66) | RAB9ALMNANPC1KDM4ENFKB1 | |
| SCHEMBL9911645 | 0.80 | RAB9A (0.77) | RAB9ALMNANPC1KDM4ENFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518978-B2 | Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-27 | — | — | US | claimed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | disclosed |
| US-8518978-B2 | Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-27 | — | — | US | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005269-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK HOLDINGS CO., LTD. (KR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | PTGIR, GPR119, PTGIS | RAB9A 2717/4885LMNA 2579/4885NPC1 1805/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | RAB9A 2013/4885LMNA 2934/4885NPC1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.